News: FDA advisory committee unanimously recommends approval of Novartis investigational treatment FTY720 to treat relapsing remitting MS

Share this postShare on Google+Share on LinkedInShare on FacebookTweet about this on TwitterEmail this to someone

The Roskamp Institute continues to actively recruit clinical research participants for the treatment of both Alzheimer’s disease and Multiple sclerosis. We are proud to share the following press announcement regarding a clinical trial/potential treatment that Roskamp Institute has been involved in since 2006: “FDA advisory committee unanimously recommends approval of Novartis investigational treatment FTY720 to treat relapsing remitting MS”.

The Roskamp Institute Memory Clinic and Clinical Trials Division provide a full range of services for individuals with Alzheimer’s disease including diagnostic work-up and follow-up treatment, neuropsychological examination, clinical trial opportunities, and memory screening.  For more information, please call (941) 256-8018.